Mission Therapeutics’ Collaboration with AbbVie Nominated for Scrip Best Partnership Alliance Award

/in

CAMBRIDGE, UK – 16 September 2019 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively inhibiting deubiquitylating enzymes (DUBs), announced today that its collaboration with research-based global biopharmaceutical company, AbbVie (“AbbVie”)(NYSE: ABBV), has been shortlisted for the 2019 Scrip Best Partnership Alliance Award.

Mission and AbbVie are working together in the research and preclinical development of DUB inhibitors for the treatment of Alzheimer’s and Parkinson’s diseases. As the most common forms of neurological disorder, over 50 million people worldwide are living with dementia and Alzheimer’s, and 10 million more with Parkinson’s.

Under the terms of the agreement, the Companies will collaborate to identify specific DUBs of interest and discover suitable inhibitor compounds. AbbVie will then have the option to gain exclusive rights to develop and commercialise compounds against up to four selected targets.

Dr. Anker Lundemose, Chief Executive Officer at Mission, commented:

“It is an honour that our collaboration with AbbVie has been selected as a finalist for the Best Partnership Alliance Award by the expert panel. Partnering with AbbVie has been instrumental for our research and we are pleased that our work with them is being recognised within the industry. We look forward to attending the ceremony and celebrating the huge progress that has been made across the pharmaceutical and biotech industries this year.”

The winners of the 2019 Scrip Awards will be announced at the awards dinner on 4 December in London.

  

FOR MORE INFORMATION:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

T: +44 (0) 1223 607340

 

 Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul

T: +44 (0) 20 7457 2020

E: missiontherapeutics@instinctif.com

 NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

In November 2018, Mission Therapeutics and AbbVie entered into a collaboration in the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. Mission has strong links with key academic and research centers, including Prof. Steve Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

For more information, please visit our website, www.missiontherapeutics.com, or follow us on Twitter or LinkedIn.

Dr. James Summers Appointed to Mission Therapeutics’ Board of Directors

/in

CAMBRIDGE, UK – 1 May 2019 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), today announced the appointment of Dr. James Summers as an independent member to its Board of Directors, with immediate effect.

Dr. Summers brings over 30 years of drug discovery and pharmaceutical research management experience to Mission’s Board. His most recent position was as Vice President of Neuroscience Research at AbbVie, where he led drug discovery efforts in the treatment of Alzheimer’s and Parkinson’s diseases, pain, and psychiatric disorders.

Dr. Colin Goddard, Non-Executive Chairman of the Board of Directors at Mission, said:

“We are pleased to welcome Dr. Summers to our Board of Directors. Jim has spearheaded numerous transactions for AbbVie in the area of neurological disorders, including Mission’s collaboration with AbbVie for the development of DUB inhibitors to treat Alzheimer’s and Parkinson’s diseases. We believe his appointment as a Director will bring immense domain knowledge to our deliberations as a board and I look forward to working with him in his new role.”

Dr. Anker Lundemose, Chief Executive Officer at Mission, added:

“Since the start of the AbbVie collaboration in November 2018, the Mission team has already benefited from the strength of Jim’s specialist knowledge and sector experience. We believe that he will be of tremendous value to the Company as we continue to progress our therapeutic pipeline”.

Dr. James Summers, newly appointed Non-Executive Director at Mission, also commented:

“In addition to its best-in-class DUB technology platform, Mission has researchers with a unique understanding of the science behind Alzheimer’s and Parkinson’s diseases. I am thrilled to have the opportunity to continue to support the Company as it works towards developing new treatments that positively impact the lives of patients with these debilitating diseases.”

Prior to his role at AbbVie, Dr. Summers was Divisional Vice President of Advanced Technology with Abbott, where he managed the organisation responsible for the diverse technologies and services that enable effective drug discovery research across the company. He has established new research sites in Cambridge, Massachusetts and Shanghai, China and led the way in refocusing the research strategies of this global organisation. He has also championed multiple successful deals, collaborations and investments and advanced more than 20 compounds into clinical development.

Dr. Summers earned his Bachelor of Science degree, summa cum laude, in chemistry from Denison University and his doctorate in organic chemistry from Harvard University.

 

FOR MORE INFORMATION:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

T: +44 (0) 1223 607340

 

 Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul

T: +44 (0) 20 7457 2020

E: missiontherapeutics@instinctif.com

  

 

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

 In November 2018, Mission Therapeutics and AbbVie entered into a collaboration in the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

For more information, please visit our website, www.missiontherapeutics.com, or follow us on Twitter or LinkedIn.

Mission Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference

/in

CAMBRIDGE, UK – 6th March 2019 –Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), announced today that Dr Anker Lundemose, CEO, will present a company overview at the Cowen and Company 39th Annual Healthcare Conference, in Boston, Massachusetts.

The presentation will take place on Tuesday 12th March at 8.00 am ET.

ENDS

FOR MORE INFORMATION:

Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0) 1223 607340		 Instinctif Partners
Melanie Toyne-Sewell / Eileen Paul
Tel: +44 (0) 20 7457 2020
missiontherapeutics@instinctif.com

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

In November 2018, Mission Therapeutics and AbbVie entered into a collaboration in the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed a £60m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

Dr Nick Edmunds Appointed to VP, Head of DUB Discovery

/in

CAMBRIDGE, UK – 3 December 2018 –Mission Therapeutics, a drug discovery and development company focused on treating mitochondrial diseases, fibrosis and neurodegenerative disorders by selectively inhibiting deubiquitylating enzymes (DUBs), has appointed Dr Nick Edmunds as Vice President, Head of DUB Discovery, with immediate effect.

Dr Edmunds has over 15 years’ pharmaceutical industry experience and a track record of delivery across small molecule preclinical drug discovery and early clinical development. He joined Mission as a Senior Director in September from AstraZeneca, where he had previously held a number of senior roles in Drug Safety and Metabolism, including Senior Director, Head of New Modalities and Director of Safety Pharmacology.

Prior to that, he was a Research Fellow at Pfizer Global Research and Development, Groton, USA and the Cardiovascular Discipline Leader in Global Safety Pharmacology at Pfizer Global Research and Development, Sandwich, UK.  Dr Edmunds carried out his postdoctoral research studies in the Department of Physiology, University of Birmingham, UK. He also holds a PhD from the Pharmacy and Pharmacology Department, University of Bath, UK and a BSc in Pharmacology from the University of Leeds, UK.

Dr Anker Lundemose, Mission’s CEO, said:

“I am very pleased to welcome Nick to Mission Therapeutics’ Management team, especially at this exciting time following the announcement of a major collaboration with AbbVie. Nick has the right skills, experience, enthusiasm and mindset to provide superb leadership to our research team and to advance our discovery DUB programmes.”

His internal appointment follows Dr Anne Phelan’s decision to step down as Executive Vice President of Research.

Dr Anker Lundemose, added:

“I would like to thank Anne for providing excellent leadership to our research team. We will miss her and wish her all the very best with her future endeavours.”

Dr Nick Edmunds, newly appointed, Vice President, Head of DUB Discovery at Mission Therapeutics, said:

“Mission has been leading the way with its research in the DUBs field and so I am really looking forward to being part of the management team. The potential of the in-house programmes as well as the recent collaboration with AbbVie make this an exciting time to help take the Company forward.”

 

FOR MORE INFORMATION:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 (0) 1223 607340

 

 Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul

Tel: +44 (0) 20 7457 2020

missiontherapeutics@instinctif.com

 

  

 

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases, and fibrosis. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

In November 2018 Mission Therapeutics and AbbVie entered into a collaboration in the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease. Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

Mission Therapeutics and AbbVie sign DUBs Collaboration in Alzheimer’s and Parkinson’s Disease

/in

Collaboration combines Mission’s unique science, chemistry and proprietary enzyme platform with AbbVie’s strong neurodegenerative disease research, development and commercialisation capabilities

CAMBRIDGE, UK and NORTH CHICAGO, ILL, USA – 15th November 2018 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) and AbbVie (“AbbVie”)(NYSE: ABBV), a research-based global biopharmaceutical company, today announced a collaboration in the research and preclinical development of specified DUB inhibitors for the treatment of Alzheimer’s Disease and Parkinson’s Disease.

Alzheimer’s and Parkinson’s diseases are associated with the accumulation of misfolded, toxic proteins, which are believed to cause impaired function and death of nerve cells in the brain. DUBs play an important role in keeping a cell healthy by regulating the degradation of these proteins. There are over 100 different DUBs in humans. By modulating specific DUBs within the brain, AbbVie and Mission are aiming to develop potential therapeutics that enable the degradation of these toxic proteins and prevent their accumulation.

Alzheimer’s and Parkinson’s disease are the most common forms of neurological disorders.  In 2017, an estimated 50 million people were living with dementia and Alzheimer’s disease; this number is expected to double every 20 years, reaching 75 million by 2030. More than 10 million people worldwide are living with Parkinson’s disease. There are currently no treatments to stop or reverse either disease’s progression, only to alleviate the symptoms.

Dr James B Summers, Vice President, Neuroscience Discovery Research, AbbVie said:

“There is an urgent need for new treatments that will make a positive impact on the lives of patients with Alzheimer’s and Parkinson’s disease. Mission’s scientists have developed impressive early research toward the understanding of these diseases. Together, we will work to advance this early science and develop meaningful therapies.”

Commenting on the collaboration, Dr Anker Lundemose, Mission CEO said: “AbbVie is one of the world’s leading biopharmaceutical companies, therefore having them as our first major collaborator is a great validation of our science. It also marks a significant milestone in our strategic aim of realising some of the value of our DUB expertise through key industry partnerships.

He added, “The AbbVie team brings complementary capabilities and expertise as well as finance, and we greatly anticipate working with them. Together we can advance the development of Mission’s best-in-class, DUB technology platform to find effective treatments for these unmet neurodegenerative diseases.”

No financial details have been disclosed. Under the terms of the agreement, both parties will collaborate during the research stage to identify specific DUBs and discover suitable compounds. AbbVie will then have the option to gain exclusive rights to develop and commercialize DUB inhibitors against up to four selected targets. AbbVie will pay Mission an upfront license fee and Mission is also eligible to receive success-based milestone payments and royalty payments for each commercialized product.

The collaboration does not include any of Mission’s lead DUB programs including USP30 and USP10.

 

FOR MORE INFORMATION:

Mission Therapeutics Ltd
Anker Lundemose MD PhD
Chief Executive Officer
Tel: +44 (0)1223 607 340

Instinctif Partners
Melanie Toyne-Sewell / Eileen Paul
Tel: +44 (0) 20 7457 2020
missiontherapeutics@instinctif.com

AbbVie
Adelle Infante, Director External Communications
Tel: +1 847-938-8745
adelle.infante@abbvie.com

  

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases, fibrosis and inflammation. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including
leading UK centres in neurodegenerative diseases as well as Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and has operations based at the Babraham Research Campus, and nearby Granta Park, Cambridge, UK.

For more information about Mission, visit us at www.missiontherapeutics.com

Follow@MISSIONTherapeu on twitter, or LinkedIn.

About AbbVie

AbbVie is a global, research and development-based biopharmaceutical company committed to developing innovative advanced therapies for some of the world’s most complex and critical conditions. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to markedly improve treatments across four primary therapeutic areas: immunology, oncology, virology and neuroscience. In more than 75 countries, AbbVie employees are working every day to advance health solutions for people around the world.

For more information about AbbVie, please visit us at www.abbvie.com.

Follow @abbvie on Twitter, Facebook, or LinkedIn.

 

 

Mission Therapeutics Strengthens Clinical Development Team with Appointment of Dr Judit Molnar as Senior Director, Translational Medicine

/in

CAMBRIDGE, UK – 4 September 2018 – Mission Therapeutics (“Mission”), a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat mitochondrial diseases, fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Judit Molnar, MD, PhD to Senior Director of Translational Medicine with immediate effect.

Judit has over ten years of experience in translational science and early drug development of which nine years were spent working in the pharmaceutical industry. She has led small molecule drug development programmes across a variety of therapeutic areas including inflammation and fibrotic disorders, which have resulted in lead candidates being progressed from the preclinical stage into the clinic up to Phase II.

Commenting on the appointment, Dr Paul Thompson, Vice President, Clinical Development at Mission said:

“We are pleased to welcome Judit to Mission’s clinical leadership team. Judit’s in-depth clinical knowledge and proven drug development track record will further strengthen our team as we work to translate scientific advances in the DUB field into transformative therapeutics for mitochondrial diseases and fibrosis.

“She joins Mission at an opportune moment as we have just selected a lead candidate inhibitor for our USP30 programme in mitochondrial diseases and fibrosis. Her expertise and insights will prove invaluable as we progress this programme towards clinical studies during 2019.”

Dr Judit Molnar, newly appointed Senior Director, Translational Medicine, Mission Therapeutics, said:

“Mission’s unique science, chemistry and DUB platform, applicable across numerous therapeutic areas with high unmet need, is highly impressive. I am looking forward to working alongside the experienced and dedicated leadership team to advance its ambitious USP30 and other programmes through preclinical and into clinical development.”

Judit joins Mission from GlaxoSmithKline where she was Preclinical Biology Lead in Epigenetics in immuno-inflammation before being promoted to Director of Translational Medicine in 2016. Prior to this she worked from 2008 at Pfizer as a Drug Discovery Scientist and Daphne Jackson Research Fellow. Previously, she was a Research Fellow at Mount Sinai School of Medicine, New York, USA. Judit obtained a PhD in Physiology from Cornell University, New York, USA and completed her medical degree at the Semmelweis University, Budapest, Hungary.

 

FOR MORE INFORMATION:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 (0) 1223 607340

Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul / Priya Kalia

Tel: +44 (0) 20 7457 2020

missiontherapeutics@instinctif.com

 

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases, fibrosis and inflammation. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

Mission Therapeutics Appoints Dr Bobby Soni to its Board of Directors

/in

CAMBRIDGE, UK – 8 March 2018 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat fibrosis, neurodegenerative and other diseases, today announced the appointment of Dr Bobby Soni to its Board of Directors with immediate effect. Bobby replaces Rob Woodman as the representative for IP Group plc.

Bobby is currently Director of Healthcare Investments at Touchstone Innovations, now part of the IP Group plc. He joined Touchstone Innovations (previously Imperial Innovations) in 2015 from Novo Seeds, the early stage investment arm of Novo AS where he worked as Investment Director. Bobby has 17 years’ experience in the Life Science industry covering drug development, business development and venture capital investment. He is a Non-Executive Director of Storm Therapeutics, Enterprise Therapeutics, Artios Pharma, Pulmocide, and Autifony.

Bobby has a PhD in Biology from the University of Virginia and an undergraduate degree in Biochemistry from the University of Rochester.

Commenting on the appointment, Dr Anker Lundemose, Mission’s CEO, said:

“On behalf of the Board I am pleased to welcome Bobby to the Board of Mission Therapeutics. His strong life sciences background and range of experiences within the pharmaceutical and biotechnology sectors will be invaluable as Mission builds its pipeline of first-in-class therapeutic assets across multiple serious disease areas. I would also like to thank Rob for his valuable contribution to Mission and wish him every success in the future.”

 

FOR MORE INFORMATION:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 (0) 1223 497199

Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul / Priya Kalia

Tel: +44 (0) 20 7457 2020

missiontherapeutics@instinctif.com

 

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases, fibrosis and inflammation. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

Mission Therapeutics Strengthens Senior Management Team with Appointment of Dr Paul Thompson, Vice President, Clinical Development

/in

CAMBRIDGE, UK – 1 March 2018 – Today Mission Therapeutics, a drug discovery and development company focused on treating fibrosis, neurodegenerative and other diseases by selectively targeting deubiquitylating enzymes (DUBs), announced the promotion of Dr Paul Thompson to Vice President, Clinical Development with immediate effect.

Dr Thompson has over 15 years’ experience in translational research and early clinical development. He joined Mission as Medical Director for CNS in 2016 from ONO Pharma UK, where he was Clinical Science Director. Prior to this he worked at GlaxoSmithKline, where he led global project teams as Director of Discovery Medicine in Neurology, following previous roles in laboratory biomarker research and experimental medicine study leadership. Dr Thompson holds an MBiochem from the University of Oxford and a PhD in Immuno- and Cell Biology from UCL.

He is also a member of the British Pharmacological Society, Society for Neuroscience and American Academy of Neurology, and is currently the Principal Investigator on a Target Validation award from the Michael J Fox Foundation.

Commenting on the appointment, Dr Anker Lundemose, Mission’s CEO, said:

“Paul’s promotion reinforces our drug discovery and development expertise as we continue our mission to translate scientific advances in the DUB field into transformative therapies. He has already made a substantial contribution to the development of our internal pipeline. He will continue to play a pivotal role in driving the pre-clinical validation and prioritisation of our first-in-class compounds as we progress them towards clinical testing.”

Dr Paul Thompson, newly appointed VP, Clinical Development, Mission Therapeutics, said:

“This is an exciting opportunity to further influence and shape the Company’s therapeutic programs at the senior management level. I look forward to working with the team to continue improving our understanding of DUBs as therapeutic targets and their multiple potential applications to serious diseases with high unmet need, including fibrosis, rare mitochondrial disease and neurodegeneration.”

 

FOR MORE INFORMATION:

 Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 (0) 1223 497199

 Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul / Priya Kalia

Tel: +44 (0) 20 7457 2020

missiontherapeutics@instinctif.com

 

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, rare mitochondrial diseases, fibrosis and inflammation. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations (now part of IP Group) and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

Mission Therapeutics’ Highlights Positive Parkinson’s Disease USP30 Target and Inhibitor Data at the Society for Neuroscience 2017 Annual Meeting

/in

CAMBRIDGE, UK –15 November 2017 – Mission Therapeutics, the leading drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, fibrosis, and other diseases with high unmet medical need, is presenting two posters with new research and preclinical data from its USP30 inhibitor Parkinson’s disease programmes today at Neuroscience 2017, the 47th Annual Meeting of the Society for Neuroscience, in Washington, DC. The meeting is the world’s largest neuroscience conference.

USP30 is a mitochondrial-associated DUB that has emerged as a promising new target in Parkinson’s disease. It has been implicated in the control of mitophagy, a cellular mitochondrial quality control mechanism. This process regulates the selective clearance of poorly functioning mitochondria by modifying levels of a protein called ubiquitin.

Failure of mitochondrial quality control results in the accumulation of dysfunctional energy-producing mitochondria, which causes oxidative stress. This stress eventually leads to a pathological mechanism that can result in Parkinson’s disease, and involves the degeneration of the highly-active substantia nigra neurons in the brain. Mission Therapeutics is developing potent and selective inhibitors against USP30 which can help improve mitochondrial quality control, with the aim of halting or slowing down the development of Parkinson’s.

Dr Anker Lundemose, Chief Executive Officer of Mission Therapeutics, said:

“DUBs are playing an emerging role as targets across a number of serious diseases, as highlighted in our team’s recently-published Nature Reviews Drug Discovery paper. The data from the studies presented at this conference further enhances our understanding of the cellular mechanisms of USP30 and the significance of inhibiting this particular DUB in Parkinson’s disease. Our research is also providing invaluable information that is helping to shape our preclinical development strategy.”

Details of Poster Presentations:

Poster# 759.03/Title: USP30 inhibitors for Parkinson’s Disease

Poster# 759.04/Title: Targeting USP30 in Parkinson’s iPSC-derived dopamine neurons

Session Title: The Pathogenesis Mechanisms of Mitochondria in Parkinson’s Disease

Session Number: 759

Session Time: Wednesday November 15th, 2017 1.00 pm – 5:00 pm ET

The meeting will be attended by two scientists from Mission Therapeutics’ CNS team: Dr Paul Thompson, Medical Director, CNS Translational Medicine and Dr Marc Watson. Principal Scientist, CNS.

 

FOR MORE INFORMATION:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 (0) 1223 497199

Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul / Priya Kalia

Tel: +44 (0) 20 7457 2020

missiontherapeutics@instinctif.com

Westwicke Partners (U.S.)

Chris Brinzey

Tel: +1 339-970-2843

Chris.brinzey@westwicke.com

 

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, fibrosis, inflammation, cancer and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.

 

 

Mission Therapeutics’ Scientists Presenting Novel Parkinson’s USP30 Target and Inhibitor Data at the Society for Neuroscience 2017 Annual Meeting

/in

 

CAMBRIDGE, UK – November 1 2017 – Mission Therapeutics, the leading drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat neurodegenerative diseases, is presenting research and preclinical data on its USP30 inhibitor Parkinson’s disease programmes as two posters at Neuroscience 2017, the 47th Annual Meeting of the Society for Neuroscience, in Washington, DC. The meeting is the world’s largest neuroscience conference.

Mission Therapeutics’ CNS scientists Dr Paul Thompson, Medical Director, CNS Translational Medicine and Dr Marc Watson. Principal Scientist, CNS will be available to meet during the conference: To arrange a time, email: info@missiontherapeutics.com

Details of Poster Presentations:

Poster #759.03/Title: USP30 inhibitors for Parkinson’s disease

Poster #759.04/Title: Targeting USP30 in Parkinson’s iPSC-derived dopamine neurons

Session Title: The Pathogenesis Mechanisms of Mitochondria in Parkinson’s Disease

Session Number: 759

Session Time: Wednesday November 15th, 2017 1.00 pm – 5:00 pm ET

 

FOR MORE INFORMATION:

Mission Therapeutics Ltd

Anker Lundemose MD PhD

Chief Executive Officer

Tel: +44 (0) 1223 497199

Instinctif Partners

Melanie Toyne-Sewell / Eileen Paul / Priya Kalia

Tel: +44 (0) 20 7457 2020

missiontherapeutics@instinctif.com

Westwicke Partners (U.S.)

Chris Brinzey

Tel: +1 339-970-2843

Chris.brinzey@westwicke.com

 

NOTES TO EDITORS:

About Mission Therapeutics

Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of neurodegenerative disease, fibrosis, inflammation, cancer and other diseases of unmet need. The Company has built a leading platform for the discovery and development of first-in-class, small-molecule drugs that selectively target deubiquitylating enzymes (DUBs) – an emerging drug class that is attracting significant commercial interest in the area of protein homeostasis.

Mission has strong links with key academic and research centers, including Prof. Jackson’s Cancer Research UK Laboratories at the University of Cambridge Gurdon Institute, and leading UK centres in neurodegenerative diseases. The Company is managed by a team with broad international, commercial and clinical-science experience.

In February 2016, the Company completed an $86m financing that was led by Imperial Innovations and Woodford Patient Capital Trust and included participation from existing investors Sofinnova Partners, Roche Venture Fund, Pfizer Venture Investments and SR One. Mission Therapeutics was founded in 2011 and is based at the Babraham Research Campus, Cambridge, UK.